In the ECHELON-3 study, the brentuximab vedotin combination with lenalidomide and rituximab reduced mortality risk by 37% compared with placebo.

Matthew Matasar, MD, discussed what the findings from the ELM-1 trial of odronextamab in diffuse large B-cell lymphoma mean ...

Enhanced assay granted approval by New York State’s Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ is the only DLBCL MRD ...

During a Case-Based Roundtable® event, Natalie Galanina, MD, reviewed how outcomes have changed in patients with primary ...

Up to one-third of all people with non-Hodgkin's lymphoma have diffuse large B-cell lymphoma (DLBCL). DLBCL grows quickly, but it's possible to cure it. Most people learn they have this type after ...

Yes, say the authors of a new study, which found that a mere 5% of routine follow-up visits among patients with diffuse large B-cell lymphoma (DLBCL) in remission resulted in detection of relapse.

A year after the FDA rejected its marketing application for CD20xCD3 bispecific antibody odronextamab to treat two common ...

Sellas Life Sciences has reported the multicentre Phase IIa trial data of a highly selective cyclin-dependent kinase 9 (CDK9) inhibitor, SLS009, in treating relapsed/refractory diffuse large B ...

Columvi plus chemotherapy showed a 41% reduction in the risk of death in the pivotal phase III STARGLO study1,2 DLBCL—an ...

Odronextamab demonstrated a manageable safety profile and generated durable responses in patients with R/R DLBCL who have ...

Antengene’s new drug application (NDA) for Xpovio (selinexor) has gained approval from the Indonesia National Agency of Drug ...

CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today announced the submission of a Phase Ib clinical trial application ...